Published in JAMA on November 17, 2010
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | NCT00108953
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther (2011) 1.72
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66
The search for an effective partner for sorafenib: the failure of doxorubicin. Gastroenterology (2011) 1.45
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol (2013) 1.23
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem (2011) 1.19
Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17
Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest (2012) 1.11
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol (2015) 1.05
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol (2016) 0.97
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther (2011) 0.96
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun (2015) 0.95
Laser ablation for small hepatocellular carcinoma. Radiol Res Pract (2011) 0.95
Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist (2013) 0.94
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol (2012) 0.94
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol (2015) 0.93
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist (2014) 0.89
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol (2012) 0.88
Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med (2011) 0.88
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. PLoS One (2013) 0.87
N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation. Cancer Sci (2014) 0.87
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chin J Cancer (2013) 0.86
Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol (2012) 0.86
Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer (2015) 0.86
Dysphonia induced by anti-angiogenic compounds. Invest New Drugs (2013) 0.86
Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol (2014) 0.86
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology (2013) 0.86
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.84
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci (2014) 0.84
Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Targeted therapy in hepatocellular carcinoma. Int J Hepatol (2011) 0.82
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.82
Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells. Cancer Biol Ther (2014) 0.82
Up regulation of NAT10 promotes metastasis of hepatocellular carcinoma cells through epithelial-to-mesenchymal transition. Am J Transl Res (2016) 0.80
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One (2014) 0.80
Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives. World J Gastroenterol (2011) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res (2013) 0.80
Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer (2015) 0.80
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer (2013) 0.79
Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells. Oncotarget (2015) 0.79
Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2015) 0.79
Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget (2016) 0.79
Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol (2017) 0.79
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol (2015) 0.78
Systemic therapy in hepatocellular carcinoma. Clin Liver Dis (2011) 0.78
Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol (2015) 0.78
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol (2015) 0.78
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol (2015) 0.78
Current status of multimodal & combination therapy for hepatocellular carcinoma. Indian J Med Res (2012) 0.78
Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. Chin J Cancer Res (2011) 0.78
Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor. Mol Cell Endocrinol (2014) 0.78
New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin (2017) 0.77
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer (2016) 0.77
Challenges of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. Surgery (2014) 0.77
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma. JAMA (2011) 0.76
Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat (2011) 0.76
Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res (2013) 0.76
Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist (2014) 0.76
Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol (2017) 0.75
Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther (2015) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. Cancers (Basel) (2012) 0.75
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma (2014) 0.75
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.75
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget (2015) 0.75
Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Mol Clin Oncol (2014) 0.75
Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nat Rev Clin Oncol (2011) 0.75
Advanced hepatocellular carcinoma in adolescence associated with congenital cholestasis: a case description. Case Rep Oncol (2013) 0.75
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol (2017) 0.75
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget (2017) 0.75
Hepatocellular Cancer: New Kids on the Block. Gastrointest Tumors (2015) 0.75
Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75
Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol (2016) 0.75
A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. Drugs R D (2017) 0.75
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases (2015) 0.75
Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol (2017) 0.75
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clin Transl Gastroenterol (2017) 0.75
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol (2017) 0.75
Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget (2017) 0.75
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol (2013) 3.70
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol (2012) 3.56
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer (2012) 2.54
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol (2010) 1.85
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol (2010) 1.80
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
The camptothecins. Lancet (2003) 1.68
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci (2004) 1.66
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg (2002) 1.65
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol (2013) 1.62
Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol (2008) 1.61
Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD (2008) 1.59
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol (2014) 1.59
Raf-1 regulates Rho signaling and cell migration. J Cell Biol (2005) 1.58
Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg (2012) 1.58
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys (2008) 1.58
Evolving treatment of advanced colon cancer. Annu Rev Med (2009) 1.56
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol (2008) 1.54
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer (2011) 1.53
Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer (2008) 1.53
Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol (2007) 1.52
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs (2007) 1.47
Cancer transmission from organ donors-unavoidable but low risk. Transplantation (2012) 1.46
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology (2011) 1.44
A tripartite complex containing MRCK modulates lamellar actomyosin retrograde flow. Cell (2008) 1.42
Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Detection of the siphon internal carotid artery stenosis: transcranial Doppler versus digital subtraction angiography. J Neuroimaging (2009) 1.38
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol (2008) 1.33
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
The importance of mutation detection in Marfan syndrome and Marfan-related disorders: report of 193 FBN1 mutations. Hum Mutat (2007) 1.31
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
The NifL-NifA System: a multidomain transcriptional regulatory complex that integrates environmental signals. J Bacteriol (2004) 1.31
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol (2013) 1.30
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer (2007) 1.27
Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat (2012) 1.26
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Characterization of RhoA-binding kinase ROKalpha implication of the pleckstrin homology domain in ROKalpha function using region-specific antibodies. J Biol Chem (2002) 1.22
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst (2012) 1.20
Role of expression profiling in carcinoma of unknown primary remains unknown. J Clin Oncol (2013) 1.20
Sunitinib in solid tumors. Expert Opin Investig Drugs (2009) 1.20
Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol (2012) 1.20
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials (2005) 1.18
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst (2007) 1.18
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res (2005) 1.15
CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem (2009) 1.14
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer (2010) 1.14
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer (2012) 1.13
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol (2012) 1.13
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst (2011) 1.12
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer (2012) 1.12
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer (2010) 1.12
Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology (2013) 1.12
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat (2010) 1.11